<DOC>
	<DOCNO>NCT01711879</DOCNO>
	<brief_summary>This 52 week study ass use intravitreal aflibercept injection patient neovascular glaucoma ( NVG ) compare standard care panretinal photocoagulation . The investigator hypothesize neovascularization iris angle present neovascular glaucoma resolve quickly eye treat intravitreal aflibercept injection alone result increase comfort preservation visual field compare current standard care utilize pan-retinal photocoagulation . The advantage intravitreal aflibercept injection use could include resolution NVI/NVA ( neovascularization iris/neovascularization angle ) lead quicker pain relief quicker lower IOP ( intraocular pressure ) .</brief_summary>
	<brief_title>Use Intravitreal Aflibercept Injection Neovascular Glaucoma</brief_title>
	<detailed_description>The two arm study compare current common practice ( initial intravitreal anti-VEGF ( vascular endothelial growth factor ) study treatment ( VEGF ) injection ) 52 week . This single center study consist 20 patient NVG . Patients randomize : - Group A : A single injection 2mg ( 0.05ml ) intravitreal aflibercept injection baseline follow standard care laser observation total 52 week . - Group B : 2mg ( 0.05ml ) intravitreal aflibercept injection baseline follow two additional injection 4 week 8 week , every 8 week total 52 week . Clinical assessment include pain assessment ( Universal Pain Scale ) , best correct visual acuity ( ETDRS ) , ophthalmic examination , anterior segment assessment include number clock-hours NVI/NVA , gonioscopy , anterior segment photography , visual field test ( Humphrey SITA- Standard 24-2 ) , optic nerve OCT ( Zeiss Cirrus Optic Disc Cube 200x200 ) , macular OCT ( Cube scan 512 x 128 5 Line Raster ) , fluorescein angiography ( initial iris phase follow standard retinal angiography ) , concurrent medical/ocular medication . Qualitative assessment neovascularization make investigator base comparison baseline angiography .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<criteria>Patients diagnosis neovascular glaucoma ( Stage III ) Individuals ages 2190 year old ; male female race Presence neovascularization iris and/or angle At least 90 degree `` unzipped '' anterior chamber angle note gonioscopy . ( `` zip angle term use drainage angle slowly close due scar tissue neovascularization process ) Visual acuity light perception well study eye Willing able comply clinic visit studyrelated procedure Provide sign informed consent Use intravitreal antiVEGF agent study eye past 3 month . Full PRP study eye Prior vitrectomy study eye Prior trabeculectomy filtration surgery study eye Active ocular periocular infection study eye Ocular condition ( Cataract vitreous hemorrhage ) might require surgery next 12 month Allergy fluorescein dye Any past use systemic antiVEGF medication Myocardial infarction within 6 month prior study enrollment Stroke within 6 month prior study enrollment Pregnant breastfeed woman Sexually active men woman childbearing potential unwilling practice adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>